• Passa al contenuto principale
BC

biochimica clinica

it_IT Italian
it_IT Italian en_US English
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

OPINIONI - Opinions

Volume:

Biochimica Clinica 2012; 36(1) 25-28

Pubblicato on-line:

DOI:

Scarica in PDF:
Autenticazione richiesta

Perché è importante identificare e segnalare le piccole componenti monoclonali

AUTORI

Giampaolo Merlini
Laboratori di Biotecnologie, Laboratorio di Analisi Chimico-Cliniche, Fondazione IRCCS Policlinico San Matteo, Dipartimento di Medicina Molecolare, Università di Pavia

ABSTRACT

Small monoclonal immunoglobulins should not be neglected

The detection of a monoclonal immunoglobulin in serum or urine usually raises concerns about the size of the underlying B-cell-derived clone and possible systemic effects caused by its expansion. However, a small clone can synthesize a very toxic protein, producing systemic damage and protean clinical presentations.The monoclonal protein can aggregate and deposit systemically as occurs in light-chain amyloidosis, monoclonal immunoglobulin deposition disease, and monoclonal cryoglobulinemia.The clone synthesizing noxious monoclonal proteins is often small and sensitive techniques may be required to detect these immunoglobulins. A delay in diagnosis can cause irreversible organ damage and dramatically shorten survival. Prompt recognition of suggestive signs and symptoms should trigger a thorough diagnostic approach to reach the correct diagnosis quickly, as this is the key to effective therapy.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967